0001209191-21-061153.txt : 20211020
0001209191-21-061153.hdr.sgml : 20211020
20211020163201
ACCESSION NUMBER: 0001209191-21-061153
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211018
FILED AS OF DATE: 20211020
DATE AS OF CHANGE: 20211020
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LINK WILLIAM J PHD
CENTRAL INDEX KEY: 0001228684
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39112
FILM NUMBER: 211334542
MAIL ADDRESS:
STREET 1: ONE SANSOME STREET
STREET 2: SUITE 3630
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Oyster Point Pharma, Inc.
CENTRAL INDEX KEY: 0001720725
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 811030955
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 202 CARNEGIE CENTER
STREET 2: SUITE 109
CITY: PRINCETON
STATE: NJ
ZIP: 08540
BUSINESS PHONE: (609) 382-9032
MAIL ADDRESS:
STREET 1: 202 CARNEGIE CENTER
STREET 2: SUITE 109
CITY: PRINCETON
STATE: NJ
ZIP: 08540
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-10-18
0
0001720725
Oyster Point Pharma, Inc.
OYST
0001228684
LINK WILLIAM J PHD
C/O OYSTER POINT PHARMA, INC.
202 CARNEGIE CENTER, SUITE 109
PRINCETON
NJ
08540
1
0
0
0
Common Stock
2021-10-18
4
S
0
303614
14.6327
D
1057976
I
See Footnote
Common Stock
2021-10-18
4
S
0
242943
15.0939
D
815033
I
See Footnote
Common Stock
2021-10-18
4
S
0
1912
14.6327
D
6518
I
See Footnote
Common Stock
2021-10-18
4
S
0
1531
15.0939
D
4987
I
See Footnote
Common Stock
10066
D
Common Stock
20604
I
By Limited Partnership
Common Stock
1273
I
By Trust
Common Stock
27942
I
By LLC
The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by each of Versant Venture Capital IV, L.P. ("Versant IV") and Versant Side Fund IV, L.P. ("Versant Side Fund IV").
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $14.00 to $14.995, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote to this Form 4.
Shares held by Versant IV. The Reporting Person may be deemed to beneficially own the shares held by Versant IV as a managing member of Versant Ventures IV, LLC ("Versant Ventures IV"), its sole general partner. The Reporting Person disclaims beneficial ownership of the securities held by Versant IV except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $15.00 to $15.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote to this Form 4.
Shares held by Versant Side Fund IV. The Reporting Person may be deemed to beneficially own the shares held by Versant Side Fund IV as a managing member of Versant Ventures IV, its sole general partner. The Reporting Person disclaims beneficial ownership of the securities held by Versant Side Fund IV except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Shares held by Link Family Enterprise, LP. The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the controlling member of Link Family Enterprise, LP.
Shares held by The Link Family Trust. The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the Trustee of The Link Family Trust.
Shares held by Flying L Partners VII, LLC. The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the controlling member of Flying L Partners VII, LLC.
/s/ Brandon Fenn, Attorney-in-Fact
2021-10-20